P430. Long-term outcome of Crohn's disease patients treated with infliximab
B.L. Chen, S.C. Lv, T. Feng, M.Y. Li, P.S. Rao, Z.R. Zeng, P.J. Hu, M.H. Chen, First Affiliated Hospital of Sun Yat-Sen University, Department of Gastroenterology, Guangzhou, China
The use of Infliximab (IFX) has revolutionized the treatment of Crohn's disease (CD). The aim of the study was to evaluate the long-term clinical efficacy and mucosal healing of CD treated with IFX in one single center.
A total of 111 CD patients who received IFX therapy at the First Affiliated Hospital of Sun Yat-sen University were enrolled in this study. The clinical efficacy was evaluated at 10 weeks, 30 weeks, 54 weeks, 2 years, 3 years, 4 years, 5 years and 6 years respectively, whreas repeated endoscopy was performed at 10 weeks and 30 weeks.
The steroid-free remission rate at week 10, 30, and year 2, 3, 4, 5, 6 were 82.6%, 78.0%, 68.9%, 65.0%, 59.8%, 58.4% and 57.2% respectively. Mucosal healing rate at week 10 and 30 were 41.3% and 49.6% respectively. The clinical recurrence rate were 17.4%, 22.0%, 31.1%, 35.0%, 40.2%, 41.6%, 42.8% respectively. The loss of response rate were 0%, 13.6%, 13.6%, 4.5%, 4.5%, 9.1%, 4.5%, 0% respectively. Adverse effects happened in 7.4% of patients.
IFX induces and maintains high rate of long-term clinical remission and mucosal healing in CD patients. Nearly 4.5–13.6% patients lose response to IFX each year at our center.